amivantamab for nsclc with met exon 14 skipping mutations
Published 2 years ago • 503 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
3:01
update from chrysalis: amivantamab in patients with nsclc with met exon 14 skipping mutation
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
1:11
detecting the met exon 14 skipping mutations in nsclc
-
1:02
investigating met exon 14 mutations in patients with nsclc
-
0:49
the importance of metex14 testing in nsclc
-
1:36
chrysalis: amivantamab for egfr exon 20 insertion mutant nsclc
-
1:35
dr sabari on the fda approval of amivantamab/lazertinib in egfr advanced nsclc
-
1:06
gregory j. riely provides an overview of met exon 14 skipping mutations in lung cancer
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
4:27
amivantamab shows robust efficacy in post-platinum therapy patients with egfr ex20ins nsclc
-
2:49
the challenges of treating metex14 nsclc
-
1:02
dr reckamp on amivantamab in egfr exon 20–mutated nsclc
-
3:27
paloma-3: subcutaneous vs intravenous amivantamab lazertinib in refractory egfr-mutated nsclc
-
1:27
papillon phase iii primary results: amivantamab chemo vs chemo in egfr exon 20 nsclc
-
1:34
pros in papillon trial: amivantamab chemo for egfr exon 20 nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2